Prostate Cancer:
- Myriad Genetic Laboratories, Inc. Protocol: URO-008
- a long-term data collection registry study to evaluate treatment decisions and clinical outcomes in
men age 65 and older with favorable intermediate-risk prostate cancer
- Bayer HealthCare Pharmaceuticals, Inc. Protocol: 20609
- a study to compare the effects of treatment between two medications on physical function and daily
activity in men with castration-resistant prostate cancer
Enteric Hyperoxaluria:
- Allena Pharmaceuticals Protocol: ALLN-177-302
- kidney stone study to evaluate a medication to reduce oxalate excretion in patients with a history of
bariatric surgery, Crohn’s disease, short bowel or other malabsorption syndromes
Muscle Invasive Bladder Cancer:
- Animated Dynamics, Inc. Protocol: Onco4D (™) Biodynamic Chemotherapy Selection Assay
- a feasibility study of Motility Contrast Tomography for suspected muscle-invasive bladder cancer
Bladder Cancer:
- Altor Bioscience (Immunity Bio) Protocol: QUILT-3.032
- a study for patients with BCG unresponsive high-grade non-muscle invasive bladder cancer
- Altor Bioscience (Immunity Bio) Protocol QUILT-2.005
- a study for patients with high-grade non-muscle invasive bladder cancer who have never received
BCG treatment
Overactive Bladder in Men:
- Urovant Sciences Protocol URO-901-3005
- a study for males age 45 and older with overactive bladder symptoms currently on medication
therapy for enlarged prostate